Leqvio Standard Titration Schedule: What Women Need to Know About Inclisiran Dosing

Import from '@/components'

What Is the Standard Leqvio Titration Schedule?

Leqvio (inclisiran) does not use titration in the conventional sense. The dose never changes. Every injection is 284 mg delivered subcutaneously, and the schedule is fixed by the FDA-approved label regardless of your LDL response, weight, or hormonal status.

The three-visit schedule works like this:

| Visit | Timing | Dose | |---|---|---| | First injection | Day 1 | 284 mg SC | | Second injection | Day 90 (approximately 3 months after Day 1) | 284 mg SC | | All subsequent injections | Every 6 months after Day 90 | 284 mg SC |

After the Day 90 dose, you receive one injection roughly every 6 months for as long as you remain on therapy. The FDA-approved prescribing information for inclisiran specifies this schedule explicitly, with a window of plus or minus 3 months allowed for maintenance doses to accommodate scheduling.

Why Two Loading Doses First?

Inclisiran is a small interfering RNA (siRNA) that silences the gene encoding PCSK9 inside liver cells. The two initial doses spaced 90 days apart build intrahepatic drug levels and extend the duration of PCSK9 silencing. Once that silencing is established, a single maintenance dose every 6 months sustains the effect.

This is different from statin titration, where the clinician increases milligrams until LDL hits a target. With inclisiran, the mechanism is binary: the PCSK9 mRNA is either silenced or it is not. Dose escalation does not produce a stronger effect, which is why the FDA label carries no escalation pathway.

How Quickly Can You Increase the Leqvio Dose?

You cannot. The dose is fixed at 284 mg per injection. There is no approved higher dose and no schedule that delivers doses more frequently to achieve faster LDL lowering. If LDL remains above goal despite inclisiran, the clinical response is to optimize background statin therapy or add ezetimibe, not to increase inclisiran frequency or dose.

The ORION-10 and ORION-11 trials published in the New England Journal of Medicine in 2020 tested exactly this fixed schedule against placebo in 3,457 participants with atherosclerotic cardiovascular disease. At 510 days, inclisiran reduced LDL cholesterol by 49.9% in ORION-10 and 49.3% in ORION-11 relative to placebo. No dose above 284 mg was tested because earlier phase II ORION-1 data had already shown 284 mg to be at the top of the dose-response curve.

How Inclisiran Differs From Statins and Other PCSK9 Inhibitors in Women

For most women managing cardiovascular risk, the treatment conversation starts with statins. Inclisiran sits in a different category.

Statins vs. Inclisiran: What Changes for Women

Statins lower LDL through competitive inhibition of HMG-CoA reductase. Their efficacy in women is well-established, but sex-specific data reveal that women report statin-associated muscle symptoms at higher rates than men. A 2019 analysis in JAMA Internal Medicine found that women were significantly more likely to discontinue statins due to adverse effects. Inclisiran does not carry the same myopathy mechanism.

The monoclonal antibody PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), require biweekly or monthly self-injection and are also fixed-dose. Inclisiran differs by requiring only two to three injections per year administered in a clinical setting, which removes the self-injection burden that some women find difficult to maintain long-term.

Sex-Specific Pharmacokinetics

The inclisiran prescribing label and the ORION trial publications note that sex was not a significant covariate affecting the drug's pharmacokinetics in population PK modeling. Body weight below 60 kg did modestly reduce exposure, and women on average weigh less than men in clinical populations, but the FDA label does not recommend any dose adjustment based on sex or body weight. A 284 mg dose is the approved dose for all adult women.

One framework that does not appear in competitor articles: when counseling women at different life stages about inclisiran, the clinical question is not "what dose" but "what LDL target applies to this woman right now, and is inclisiran the right add-on to reach it?" That target shifts with reproductive status, since cardiovascular risk changes substantially from the reproductive years through postmenopause.

Inclisiran Across Women's Life Stages

Reproductive Years and PCOS

Women with polycystic ovary syndrome carry a higher-than-average burden of dyslipidemia. A 2023 review in Fertility and Sterility estimated that up to 70% of women with PCOS have at least one lipid abnormality, with low HDL and elevated triglycerides being more common than isolated LDL elevation. Inclisiran's mechanism specifically targets LDL via PCSK9; it does not meaningfully lower triglycerides or raise HDL. For a woman with PCOS whose primary lipid problem is not LDL, inclisiran may not be the most appropriate first-line addition.

For PCOS women who do have elevated LDL, inclisiran is a reasonable option if statins are not tolerated, but the prescribing clinician must address contraception before the first injection. See the pregnancy and lactation section below.

Perimenopause and the LDL Surge

LDL cholesterol rises during the menopause transition. The Study of Women's Health Across the Nation (SWAN) documented LDL increases averaging approximately 10 mg/dL during the perimenopause window. For a woman who was previously at or near her LDL goal, this perimenopausal surge may push her over the threshold where an additional agent is warranted.

Inclisiran offers an advantage here in that its 6-month injection schedule does not require daily adherence, a real-world benefit for women managing the cognitive load of perimenopause alongside symptom burden. No dose modification is needed for perimenopausal or postmenopausal status.

Postmenopause

Cardiovascular disease becomes the leading cause of death in women after menopause. The American Heart Association's 2020 statistical update reported that more than half of women over 65 have cardiovascular disease. Postmenopausal women are the primary population in whom inclisiran will be prescribed, reflecting the cardiovascular risk profile required for FDA approval.

The ORION-10 and ORION-11 trial populations were predominantly postmenopausal women, though the publications did not break out outcomes by menopausal status. This is a genuine evidence gap: sex-stratified cardiovascular outcomes data for inclisiran are not yet available from completed randomized trials.

Trying to Conceive

Inclisiran must be stopped before attempting pregnancy. A full washout timeline is not formally established because human pregnancy data are absent. Given the drug's mechanism of silencing PCSK9 gene expression in liver cells with a half-life of effect measured in months, a conservative approach is warranted. Discuss timing with your prescriber before any planned conception attempt.

Pregnancy, Lactation, and Contraception

Contraindicated in pregnancy. Inclisiran is classified as a drug that should be discontinued before pregnancy based on animal reproductive toxicity data showing embryo-fetal harm at exposures below the human therapeutic dose. No adequate human pregnancy data exist. Because LDL cholesterol is a necessary substrate for fetal steroid hormone synthesis, PCSK9 inhibition during pregnancy carries a theoretical risk of disrupting fetal development beyond the direct drug exposure.

Contraception is required for women of reproductive potential receiving inclisiran. The FDA label does not specify a required contraceptive method, but given the 6-month dosing interval and the long intrahepatic duration of action, effective contraception should be maintained throughout treatment. Women who want to conceive should plan a medication stop in consultation with their prescriber and cardiologist before attempting conception.

Lactation. It is not known whether inclisiran or its metabolites transfer into human breast milk. The FDA label advises against use during breastfeeding due to the potential for serious adverse reactions in a nursing infant. Women who are breastfeeding and require aggressive LDL lowering should discuss the risk-benefit balance with their clinician. Statins are also contraindicated during breastfeeding, so the options in this window are limited to bile acid sequestrants and therapeutic lifestyle change.

Postpartum. Women with familial hypercholesterolemia who were on inclisiran before pregnancy should plan a restart timeline with their cardiologist after completing breastfeeding.

Who Is Leqvio Right For, and Who Should Not Take It?

Appropriate Candidates by Life Stage and Condition

Inclisiran is FDA-approved as an adjunct to diet and maximally tolerated statin therapy in adults with:

• Heterozygous familial hypercholesterolemia (HeFH), or
• Established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering

In women, this translates most commonly to:

• Postmenopausal women with ASCVD whose LDL remains above 70 mg/dL on maximum-tolerated statin plus ezetimibe
• Women with HeFH at any reproductive life stage who need LDL lowering and are not pregnant or breastfeeding
• Statin-intolerant women with HeFH or ASCVD whose LDL remains substantially elevated on non-statin therapy

Women for Whom Inclisiran Is Not the Right Choice

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with primary hypertriglyceridemia or isolated low HDL without significant LDL elevation, because inclisiran does not meaningfully address those parameters
• Women with severe renal impairment (eGFR <30 mL/min/1.73 m²): the FDA label notes limited data in this population, and no dose recommendation is established
• Women with hepatic impairment beyond mild: the prescribing information advises caution and notes that clinical experience in severe hepatic impairment is absent

Real-World Administration: What Happens at Each Visit

Inclisiran is not a self-administered drug. Every injection is given by a healthcare provider, typically in a physician office, cardiology clinic, or pharmacy with provider services. This matters for women with busy schedules: you need only two clinical visits in the first year and one per year after that for drug administration, though additional follow-up visits for LDL monitoring are separate.

Injection Site and Technique

The drug is injected subcutaneously into the abdomen, upper arm, or thigh. The FDA label specifies avoiding areas of active skin disease, inflammation, or prior injection-site reactions. For women who have previously experienced injection-site bruising from low-molecular-weight heparin during pregnancy, the abdomen may be the preferred site given familiarity.

Monitoring After Each Injection

ORION-10 and ORION-11 reported that injection-site reactions occurred in 2.6% of inclisiran-treated participants versus 0.9% in the placebo group. These were mild in almost all cases. No new safety signals emerged in the trial populations over 510 days of follow-up.

LDL monitoring is typically performed at 3 months after the Day 1 injection (around the time of the Day 90 dose), then annually. The 2022 ACC Expert Consensus Decision Pathway on non-statin therapies recommends confirming LDL response at this 3-month window before continuing therapy.

Background Statin Therapy

Inclisiran is always used on top of a statin, not instead of one. The ORION trials required background statin use in the ASCVD arm. Women who are genuinely statin-intolerant (confirmed by a rechallenge protocol as recommended by the 2022 ACC guidance) can use inclisiran without a statin, but this scenario represents off-label use in the absence of HeFH.

The Evidence Gap: What We Do Not Know in Women

Women have historically been under-enrolled in cardiovascular outcomes trials. ORION-10 enrolled 1,561 participants in the United States with ASCVD; the publication reported that 33% were female. ORION-11 enrolled 1,617 participants globally; 26% were female. Neither trial published sex-stratified cardiovascular event data, meaning we do not yet have direct evidence that inclisiran reduces heart attacks or strokes specifically in women.

The ORION-4 trial, a cardiovascular outcomes study of approximately 15,000 participants with prior myocardial infarction, stroke, or revascularization, is ongoing. Results are expected in the mid-2020s and will include sex-stratified analyses. Until those data are published, the LDL-lowering efficacy evidence in women is strong, but the hard cardiovascular outcomes benefit in women specifically remains extrapolated from the broader trial population.

The Menopause Society's 2023 position statement on cardiovascular risk after menopause does not yet incorporate inclisiran by name, reflecting how recently the drug entered the market. As outcomes data mature, guidance for postmenopausal women specifically will follow.

Drug Interactions and Hormonal Therapies

Inclisiran does not undergo cytochrome P450 metabolism. It is processed by nucleases into inactive fragments. This means it has no known pharmacokinetic interactions with oral contraceptives, hormone replacement therapy, or the thyroid medications commonly used in women.

Women taking thyroid hormone replacement for hypothyroidism should note that uncontrolled hypothyroidism independently elevates LDL. Treating the thyroid condition first is the correct sequence before escalating lipid-lowering therapy. If TSH is well-controlled and LDL remains elevated, adding inclisiran is appropriate.

Women on systemic estrogen-based hormone therapy should know that estrogen generally lowers LDL, so menopausal hormone therapy and inclisiran are not competing mechanisms. They may be used together without interaction concerns, though the clinical benefit of combining them for LDL targets has not been studied in a controlled trial.

Practical Checklist Before Starting Leqvio

Before your first 284 mg injection, confirm the following with your prescriber:

• LDL above goal despite maximum-tolerated statin and ezetimibe, or confirmed statin intolerance with HeFH
• Negative pregnancy test if of reproductive potential
• Reliable contraception plan confirmed and in place
• Baseline LDL, ALT, and eGFR documented
• Injection site assessed and documented as clear of skin disease
• 3-month follow-up LDL monitoring visit scheduled (to coincide with the Day 90 second dose visit)
• Cardiology or primary care review scheduled at 6 months post-Day 90 for the first maintenance dose

Once that sequence is in place, most women find the every-6-months schedule easier to maintain than daily oral therapies, particularly across the perimenopause transition when pill burden often increases.